Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

05 Mar 2017 - 09 Mar 2017
20 Mar 2017 - 23 Mar 2017
12 Apr 2017 - 14 Apr 2017

Transforming Methylated Nucleic Acids into Prostate Tumor Biomarkers

By BiotechDaily International staff writers
Posted on 06 Apr 2014
ADVERTISEMENT
SARTORIUS AG
High quality oligonucleoside reagents and detection kits are facilitating research on methylated DNA and its relation to the molecular mechanisms that drive development of prostate cancer.

In the March 31, 2014, online edition of the Integrated DNA Technologies (Coralville, IA, USA) newsletter DECODED, Dr. Antoinette Perry, senior research fellow at the Institute of Molecular Medicine (Dublin, Ireland), described how use of materials supplied by Integrated DNA Technologies (IDT) facilitated her research team's study of prostate cancer.

Research in Dr. Perry’s laboratory is directed at understanding how changes in DNA methylation of coding and non-coding RNA genes are involved in driving prostate carcinogenesis. The investigators exploit specific epigenetic changes for early, noninvasive detection of aggressive prostate cancer. In the process, they hope to develop predictive epigenetic biomarkers—focusing both on circulating free nucleic acids and exosomes—that can be quantified by simple, liquid biopsy. Ultimately, they hope to use these biomarkers to develop a noninvasive test that will distinguish high-risk from lower-risk prostate tumors.

Among the tools being used are IDT PrimeTime qPCR Assays and ZEN Double-Quenched Probes. These probes increase the accuracy and reliability of 5’ nuclease qPCR experiments. They contain an internal quencher only nine bases from the 5’ fluorescent label. This shortened distance, particularly when combined with the standard 3’ quencher, significantly decreases background fluorescence and increases sensitivity. Since, the initial background fluorescence signal is much lower than with traditional probes, it is much easier to detect subsequent changes and, therefore, functionally increases assay sensitivity.

Integrated DNA Technologies is one of the largest suppliers of custom nucleic acids in the United States, serving academic, government, and commercial researchers in biotechnology, clinical diagnostics, and pharmaceutical development.

Related Links:
Integrated DNA Technologies
Institute of Molecular Medicine



Channels

Drug Discovery

view channel
Image: The experimental drug NGI-1 slows cancer growth by blocking glycosylation of the epidermal growth factor receptor (EGFR), which is shown in the above diagram (Photo courtesy of Wikimedia Commons).

Experimental Drug Slows Lung Cancer Growth by Blocking Protein Glycosylation

An interesting new experimental anti-cancer drug slows growth of certain lung tumor cells by preventing the glycosylation of critical cell surface receptor proteins. Asparagine (N)-linked glycosylation... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Business

view channel

Collaborative Agreement to Aid in Setting Guidelines for Evaluating Potential Ebola Therapy

Cooperation between an Israeli biopharmaceutical company and medical branches of the US government is designed to set ground rules for continued evaluation of an experimental therapy for Ebola virus disease. RedHill Biopharma Ltd. (Tel Aviv, Israel), a biopharmaceutical company primarily focused on development and c... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.